Hcw Biologics INC 8-K filings

HCW Biologics Inc. announced its second quarter 2026 financial results, highlighting positive preliminary data for its HCW9302 drug candidate and significant revenue growth, while also addressing ongoing financial challenges.

HCW Biologics Inc. announced that its previously issued unaudited condensed financial statements for the three months ended March 31, 2026, should no longer be relied upon due to an error in earnings per share calculation.

HCW Biologics Inc. announced the pricing of a $1.6 million private placement offering, including units with common stock or pre-funded warrants and common warrants, subject to stockholder approval.

HCW Biologics Inc. announced the settlement and extinguishment of $2.8 million in disputed accounts payable, resolving legal and manufacturing cost disputes.

HCW Biologics Inc. has regained compliance with Nasdaq's Bid Price Rule and will implement a one-for-six reverse stock split to ensure continued listing.

HCW Biologics will implement a 1-for-6 reverse stock split effective June 30, 2026, to maintain Nasdaq listing compliance.

HCW Biologics announced positive preliminary human data from its Phase 1 trial of HCW9302, an IL-2 based fusion immunotherapeutic, showing encouraging results in patients with alopecia areata.

HCW Biologics Inc. announced the results of its 2026 Annual Meeting of Stockholders, where key proposals including a reverse stock split authorization and warrant repricing were approved.

HCW Biologics Inc. has received an extension from Nasdaq to regain compliance with the minimum bid price rule, with a deadline of July 29, 2026.

HCW Biologics Inc. has exercised its option to regain full ex vivo rights for HCW9206 and HCW9201, positioning the company to capitalize on the growing CAR-T immunotherapy market.

HCW Biologics Inc. announced the pricing of a private placement offering, raising approximately $4.0 million to fund clinical trials and advance drug development.

HCW Biologics adjourned its April 27 special meeting due to a lack of quorum and will move proposals to the June 15 annual meeting.

HCW Biologics has amended its bylaws to reduce the shareholder meeting quorum requirement to 33 1/3% of voting power.

HCW Biologics announced its fourth quarter and fiscal year 2025 financial results, highlighting clinical trial progress and a licensing deal amidst significant financial challenges and Nasdaq compliance issues.

HCW Biologics announced the closing of an exclusive worldwide license for its molecule HCW11-006, securing a $7.0 million upfront payment and future milestones.

HCW Biologics Inc. announced it has regained full compliance with all Nasdaq Capital Market continued listing rules, securing its access to public markets.

HCW Biologics Inc. announced a $1.5 million follow-on offering of units, each comprising common stock or pre-funded warrants and common stock warrants, alongside a proposed amendment to existing warrants.

HCW Biologics Inc. announced an exclusive worldwide license agreement for its HCW11-006 molecule and an option for HCW9302 with a new joint venture, Trimmune, securing $7 million in initial consideration.

HCW Biologics Inc. announced actions taken to restore its stockholders' equity above the Nasdaq minimum requirement, including a warrant inducement, equity line draw, and a legal fee settlement.

HCW Biologics Inc. secured approximately $4.0 million in gross proceeds by inducing an institutional investor to exercise existing warrants at a reduced price, issuing new warrants in return.

HCW Biologics Inc. entered an amended licensing agreement with Beijing Trimmune Biotech Co., Ltd. for HCW11-006, including a $7.0M upfront fee and an option for HCW9302.

HCW Biologics announced the dosing of the first patient in a Phase 1 clinical trial for its lead autoimmune product candidate, HCW9302, targeting alopecia areata.

HCW Biologics Inc. announced its third quarter 2025 financial results and provided updates on its clinical development programs, including the anticipated dosing of the first patient in a Phase 1 study for HCW9302.

HCW Biologics Inc. has been granted an extension by the Nasdaq Hearings Panel until December 31, 2025, to regain compliance with the Equity Rule and avoid delisting.

HCW Biologics announced that WY Biotech will likely miss the extended September 30, 2025 deadline for its $7.0 million upfront license fee payment, prompting further negotiations.

HCW Biologics Inc. received notice of non-compliance with Nasdaq's Equity Rule, risking suspension and delisting.

HCW Biologics reported Q2 2025 financial results, highlighted a $5.0 million equity raise, extended a $7.0 million license payment, and suspended a key licensing agreement.

HCW Biologics Inc. amended its existing $20 million equity purchase agreement with Square Gate Capital to enable multiple intraday sales of common stock.

HCW Biologics reported a significantly reduced net loss in Q2 2025, achieved full Nasdaq compliance, and secured new funding, despite a sharp decline in revenue.

HCW Biologics Inc. announced an extension for the $7.0 million upfront license fee payment from WY Biotech Co., Ltd. to September 30, 2025, to accommodate WY Biotech's financing and CDMO agreements.